EP3373923A4 - FORMULATION OF L-ORNITHINE PHENYLACETATE - Google Patents
FORMULATION OF L-ORNITHINE PHENYLACETATE Download PDFInfo
- Publication number
- EP3373923A4 EP3373923A4 EP16865158.6A EP16865158A EP3373923A4 EP 3373923 A4 EP3373923 A4 EP 3373923A4 EP 16865158 A EP16865158 A EP 16865158A EP 3373923 A4 EP3373923 A4 EP 3373923A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- formulation
- ornithine phenylacetate
- phenylacetate
- ornithine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- LRSYFEZBIMVWRY-VWMHFEHESA-N (2s)-2,5-diaminopentanoic acid;2-phenylacetic acid Chemical compound NCCC[C@H](N)C(O)=O.OC(=O)CC1=CC=CC=C1 LRSYFEZBIMVWRY-VWMHFEHESA-N 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562255300P | 2015-11-13 | 2015-11-13 | |
US201662276754P | 2016-01-08 | 2016-01-08 | |
US15/133,087 US20160338982A1 (en) | 2015-04-20 | 2016-04-19 | Formulations of l-ornithine phenylacetate |
PCT/US2016/061678 WO2017083758A1 (en) | 2015-11-13 | 2016-11-11 | Formulation of l-ornithine phenylacetate |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3373923A1 EP3373923A1 (en) | 2018-09-19 |
EP3373923A4 true EP3373923A4 (en) | 2019-07-03 |
Family
ID=58695607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16865158.6A Withdrawn EP3373923A4 (en) | 2015-11-13 | 2016-11-11 | FORMULATION OF L-ORNITHINE PHENYLACETATE |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP3373923A4 (ko) |
JP (2) | JP7294807B2 (ko) |
KR (1) | KR20180086431A (ko) |
CN (2) | CN113768863A (ko) |
AU (2) | AU2016353350B2 (ko) |
BR (1) | BR112018009349A8 (ko) |
CA (1) | CA3004331A1 (ko) |
IL (1) | IL258630B2 (ko) |
MX (2) | MX2018005088A (ko) |
RU (1) | RU2018113801A (ko) |
SG (1) | SG11201802987UA (ko) |
WO (1) | WO2017083758A1 (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
PE20200747A1 (es) | 2017-08-14 | 2020-07-24 | Axcella Health Inc | Composiciones de aminoacidos para el tratamiento de enfermedad hepatica |
MA52971A (fr) | 2018-06-20 | 2021-04-28 | Axcella Health Inc | Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle |
AU2020366365A1 (en) * | 2019-10-16 | 2022-04-21 | Mallinckrodt Enterprises Llc | Dosages and uses of ornithine phenylacetate for treating hyperammonemia |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006056794A1 (en) * | 2004-11-26 | 2006-06-01 | Ucl Business Plc | Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy |
WO2010144498A2 (en) * | 2009-06-08 | 2010-12-16 | Ucl Business Plc | Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
GB0426141D0 (en) * | 2004-11-26 | 2004-12-29 | Ucl Biomedica Plc | Treatment |
DE102007009243A1 (de) * | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets |
AU2015221466B2 (en) | 2009-04-03 | 2017-02-02 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
WO2010115055A1 (en) * | 2009-04-03 | 2010-10-07 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
AU2014250643B2 (en) | 2009-06-08 | 2016-07-14 | Ocera Therapeutics, Inc. | Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate |
NZ609191A (en) * | 2010-10-06 | 2015-06-26 | Ocera Therapeutics Inc | Methods of making l-ornithine phenyl acetate |
CN103705490B (zh) * | 2013-10-31 | 2016-08-17 | 蚌埠丰原医药科技发展有限公司 | 一种门冬氨酸鸟氨酸的缓释制剂及其制备工艺 |
DK3285756T3 (da) | 2015-04-20 | 2023-05-08 | Ocera Therapeutics Inc | Formuleringer af l-ornithinphenylacetat |
-
2016
- 2016-11-11 RU RU2018113801A patent/RU2018113801A/ru not_active Application Discontinuation
- 2016-11-11 KR KR1020187016373A patent/KR20180086431A/ko active Search and Examination
- 2016-11-11 AU AU2016353350A patent/AU2016353350B2/en not_active Ceased
- 2016-11-11 BR BR112018009349A patent/BR112018009349A8/pt not_active Application Discontinuation
- 2016-11-11 WO PCT/US2016/061678 patent/WO2017083758A1/en active Application Filing
- 2016-11-11 CN CN202111062923.6A patent/CN113768863A/zh active Pending
- 2016-11-11 SG SG11201802987UA patent/SG11201802987UA/en unknown
- 2016-11-11 JP JP2018524369A patent/JP7294807B2/ja active Active
- 2016-11-11 CN CN201680066488.5A patent/CN108366983A/zh active Pending
- 2016-11-11 CA CA3004331A patent/CA3004331A1/en not_active Abandoned
- 2016-11-11 MX MX2018005088A patent/MX2018005088A/es unknown
- 2016-11-11 EP EP16865158.6A patent/EP3373923A4/en not_active Withdrawn
-
2018
- 2018-04-11 IL IL258630A patent/IL258630B2/en unknown
- 2018-04-25 MX MX2022001517A patent/MX2022001517A/es unknown
-
2021
- 2021-12-21 AU AU2021290236A patent/AU2021290236A1/en not_active Abandoned
- 2021-12-28 JP JP2021213640A patent/JP2022058446A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006056794A1 (en) * | 2004-11-26 | 2006-06-01 | Ucl Business Plc | Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy |
WO2010144498A2 (en) * | 2009-06-08 | 2010-12-16 | Ucl Business Plc | Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate |
Non-Patent Citations (5)
Title |
---|
JALAN R ET AL: "l-Ornithine phenylacetate (OP): A novel treatment for hyperammonemia and hepatic encephalopathy", MEDICAL HYPOTHESES, EDEN PRESS, PENRITH, US, vol. 69, no. 5, 27 April 2007 (2007-04-27), pages 1064 - 1069, XP029096478, ISSN: 0306-9877, DOI: 10.1016/J.MEHY.2006.12.061 * |
RUNE GANGSØY KRISTIANSEN ET AL: "L-Ornithine phenylacetate reduces ammonia in pigs with acute liver failure through phenylacetylglycine formation: a novel ammonia-lowering pathway", AMERICAN JOURNAL OF PHYSIOLOGY. GASTROINTESTINAL AND LIVER PHYSIOLOGY, 15 November 2014 (2014-11-15), United States, pages G1024 - G1031, XP055532599, Retrieved from the Internet <URL:https://www.physiology.org/doi/full/10.1152/ajpgi.00244.2014> DOI: 10.1152/ajpgi.00244.2014 * |
VAIRAPPAN BALASUBRAMANIYAN ET AL: "Ammonia reduction with ornithine phenylacetate restores brain eNOS activity via the DDAH-ADMA pathway in bile duct-ligated cirrhotic rats", AMERICAN JOURNAL OF PHYSIOLOGY - GASTROINTESTINAL AND LIVER PHYSIOLOGY, vol. 302, no. 1, 1 January 2012 (2012-01-01), US, pages G145 - G152, XP055532625, ISSN: 0193-1857, DOI: 10.1152/ajpgi.00097.2011 * |
VENTURA-COTS MERITXELL ET AL: "Safety of Ornithine Phenylacetate in Cirrhotic Decompensated Patients : An Open-label, Dose-escalating, Single-cohort Study", vol. 47, no. 10, 1 January 2013 (2013-01-01), pages 881 - 887, XP009507196, ISSN: 0192-0790, Retrieved from the Internet <URL:http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00004836-201311000-00013> DOI: 10.1097/MCG.0B013E318299C789 * |
YTREBO LARS MARIUS ET AL: "L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure", HEPATOLOGY, JOHN WILEY & SONS, INC, US, vol. 50, no. 1, 1 July 2009 (2009-07-01), pages 165 - 174, XP009164051, ISSN: 0270-9139, [retrieved on 20090218], DOI: 10.1002/HEP.22917 * |
Also Published As
Publication number | Publication date |
---|---|
IL258630B1 (en) | 2023-04-01 |
CN108366983A (zh) | 2018-08-03 |
WO2017083758A1 (en) | 2017-05-18 |
AU2016353350A1 (en) | 2018-05-10 |
CA3004331A1 (en) | 2017-05-18 |
AU2021290236A1 (en) | 2022-02-10 |
AU2016353350B2 (en) | 2021-09-23 |
MX2022001517A (es) | 2022-11-16 |
JP7294807B2 (ja) | 2023-06-20 |
EP3373923A1 (en) | 2018-09-19 |
IL258630A (en) | 2018-06-28 |
MX2018005088A (es) | 2019-05-16 |
CN113768863A (zh) | 2021-12-10 |
BR112018009349A8 (pt) | 2019-02-26 |
RU2018113801A (ru) | 2019-12-16 |
JP2018533601A (ja) | 2018-11-15 |
JP2022058446A (ja) | 2022-04-12 |
KR20180086431A (ko) | 2018-07-31 |
IL258630B2 (en) | 2023-08-01 |
BR112018009349A2 (pt) | 2018-11-13 |
SG11201802987UA (en) | 2018-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1251149A1 (zh) | L-鳥氨酸苯乙酸鹽製劑 | |
EP3383447A4 (en) | PHOTOACTIVATED PREPARATION OF HYDROGELS | |
EP3259246A4 (en) | Derivatives of sobetirome | |
EP3337502A4 (en) | STABLE ANTI-IFNAR1 FORMULATION | |
EP3288958A4 (en) | Compositions of obeticholic acid and methods of use | |
EP3438474B8 (en) | Piece of furniture | |
EP3244725A4 (en) | Growth of cryo-sprouts | |
EP3355088A4 (en) | RETRO REFLECTOR | |
EP3251067A4 (en) | Virtual point of sale | |
EP3616686B8 (en) | Sublingual formulation of riluzole | |
EP3143711A4 (en) | Computing distances of devices | |
EP3399957A4 (en) | SKIN REFRESHING COMPOSITIONS | |
EP3185687A4 (en) | Glutamic acid containing gluten-free dough | |
EP3384921A4 (en) | NEW USE OF THIOPEPTIN | |
EP3297619A4 (en) | Therapeutic uses of l-4-chlorokynurenine | |
IL258630B1 (en) | Formulation of l.-ornithine phenylacetate | |
EP3316677A4 (en) | ACTIVATOR OF JASMONIC ACID SIGNAL | |
EP3237391A4 (en) | Creatine prodrugs, compositions and methods of use thereof | |
EP3175350A4 (en) | Display of multiple instances | |
EP3384767A4 (en) | IMPROVED SPRAY | |
EP3171860A4 (en) | Solid oral formulation of fenretinide | |
EP3468578A4 (en) | USES OF IL-41 | |
EP3335238A4 (en) | PASSIVATION OF GERMANIUM SURFACES | |
EP3133934A4 (en) | Stable food coating | |
EP3338775A4 (en) | USES OF BUTYLIDENEPHTHALIDE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180503 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: GRAIS, LINDA S. Inventor name: WANG, LAURENE Inventor name: BUKOFZER, STANLEY |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: OCERA THERAPEUTICS, INC. |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20190605 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/198 20060101AFI20190529BHEP Ipc: A61K 31/195 20060101ALI20190529BHEP Ipc: C07C 57/32 20060101ALI20190529BHEP Ipc: A61K 31/192 20060101ALI20190529BHEP Ipc: A61P 1/16 20060101ALI20190529BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1263185 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20220207 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20231025 |